Related Experiment Videos
C3b receptor (CR1) on erythrocytes in various diseases
Insights
Defective erythrocyte complement receptor 1 (CR1) reactivity was found in 6% of healthy individuals. Significantly higher rates were observed in systemic lupus erythematosus and acute myelogenous leukemia patients.
Area of Science:
- Immunology
- Hematology
Background:
- Complement receptor 1 (CR1) on erythrocytes plays a crucial role in immune complex clearance.
- Deficiencies in CR1 function are implicated in various autoimmune and hematologic conditions.
Purpose of the Study:
- To investigate the prevalence of defective CR1 reactivity on erythrocytes in patients with different diseases.
- To compare CR1 reactivity in healthy individuals and patient cohorts.
Main Methods:
- Immune adherence hemagglutination (IAHA) assay was employed.
- Aggregated human IgG was used to assess CR1 binding.
- Erythrocyte CR1 reactivity was quantified in normal controls and patients with various diseases.
Main Results:
- A 6% prevalence of defective CR1 reactivity was observed in 312 healthy controls (no significant gender difference).
- Significantly elevated rates of defective CR1 reactivity were found in systemic lupus erythematosus (73%) and acute myelogenous leukemia (55%).
Conclusions:
- Defective erythrocyte CR1 reactivity is a notable finding in specific hematologic malignancies and autoimmune diseases.
- IAHA is a valuable method for detecting CR1 dysfunction, potentially aiding in disease diagnosis and management.
Abstract:
Complement receptor for C3b (CR1) on erythrocytes was investigated in various diseases by immune adherence hemagglutination (IAHA) using aggregated human IgG. In normal controls, 21 out of 312 (6%) revealed defective CR1 reactivity, and there was no difference in the prevalence of defective CR1 reactivity between female (11/157, 7%) and male (10/155, 6%). Among diseases examined significantly high prevalence of defective reactivity of CR1 on erythrocytes was seen in systemic lupus erythematosus (SLE) (22/30, 73%) and malignancy of hematopoietic system, especially in acute myelogenous leukemia (AML)(6/11, 55%).